Patents Represented by Attorney, Agent or Law Firm David L. Berstein
  • Patent number: 6410516
    Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 25, 2002
    Assignees: President & Fellows of Harvard College, Massachusetts Institute of Technology, Whitehead Instittue for Biomedical Research
    Inventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. Lebowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
  • Patent number: 6306649
    Abstract: This invention provides novel materials and methods involving the heterologous expression of transcription factors which are useful for effecting transcription of target genes in genetically engineered cells or organisms containing them. Target gene constructs and other materials useful for practicing the invention are also disclosed.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: October 23, 2001
    Assignee: ARIAD Gene Therapeutics, Inc.
    Inventors: Michael Z. Gilman, Sridaran Natesan
  • Patent number: 6303319
    Abstract: The present invention provides methods and compositions for identifying inhibitors of the interaction between phosphopeptide binding pairs, i.e., a protein domain having at least one phosphopeptide binding domain and the phosphorylated ligands that bind these domains. These inhibitors may be used for pharmaceutical compositions and in therapeutic treatments for diseases in which a phosphopeptide domain binding is implicated.
    Type: Grant
    Filed: July 15, 1998
    Date of Patent: October 16, 2001
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventor: Richard J. Rickles
  • Patent number: 6258823
    Abstract: This invention concerns derivatives of rapamycin and their antifungal uses. Also disclosed are materials and methods relevant to the identification of non-immunosuppressive antifungal rapamycin derivatives.
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: July 10, 2001
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Dennis A. Holt, Terence P. Keenan, Timothy P. Clackson, Leonard Rozamus, Wu Yang, Michael Z. Gilman
  • Patent number: 6207397
    Abstract: An in vitro assay method permits the identification of a test substance which inhibits the mutual association of two molecules. The method includes the steps of providing two components capable of mutual association, one of said components bearing a covalently linked fluorophore; preparing a mixture containing the two components and at least one test substance; irradiating the mixture with polarized light of a suitable wavelength permitting excitation of the fluorophore as indicated by emission of polarized light; measuring the degree of polarization of the emission, and determining the effect of the presence or concentration of the test substance in decreasing the observed emission polarization of a mixture of the two components alone. Inhibitory activity of the test substance correlates with decreased depolarization values.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: March 27, 2001
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Berkley A. Lynch, Ian MacNeil, Mark Zoller
  • Patent number: 6187757
    Abstract: Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.
    Type: Grant
    Filed: January 22, 1998
    Date of Patent: February 13, 2001
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Timothy P. Clackson, Michael Z. Gilman, Dennis A. Holt, Terence P. Keenan, Leonard Rozamus, Wu Yang
  • Patent number: 6165787
    Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: December 26, 2000
    Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
  • Patent number: 6140120
    Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .xi.
    Type: Grant
    Filed: September 16, 1998
    Date of Patent: October 31, 2000
    Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Steffan N. Ho, Peter Belshaw
  • Patent number: 6133456
    Abstract: New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains. The compounds are of the formulaM.sup.1 --L--M.sup.2where M.sup.1 and M.sup.2 are independently moieties of the formula: ##STR1## in which B.sup.1, B.sup.2, B.sup.3, R.sup.1, R.sup.2, n, W, X and Y are as defined.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: October 17, 2000
    Assignee: ARIAD Gene Therapeutics, Inc.
    Inventors: Dennis A. Holt, Terence P. Keenan, Tao Guo, Edgardo Laborde, Wu Yang
  • Patent number: 6117680
    Abstract: The present invention relates to novel fusion proteins which activate transcription, to nucleic acid constructs encoding the proteins and their use in the genetic engineering of cells.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: September 12, 2000
    Assignee: ARIAD Gene Therapeutics, Inc.
    Inventors: Sridaran Natesan, Michael Z. Gilman
  • Patent number: 6063625
    Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.
    Type: Grant
    Filed: September 16, 1998
    Date of Patent: May 16, 2000
    Assignees: Board of Trustees of Leland S, Stanford, Jr. University, President and Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Steffan N. Ho, Peter Belshaw
  • Patent number: 6054436
    Abstract: We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: April 25, 2000
    Assignees: Board of Trustees of Leland S. Stanford Jr. Univ., President & Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
  • Patent number: 6046047
    Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of tis invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.
    Type: Grant
    Filed: September 16, 1998
    Date of Patent: April 4, 2000
    Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw, Steffan N. Ho
  • Patent number: 6043082
    Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.
    Type: Grant
    Filed: September 16, 1998
    Date of Patent: March 28, 2000
    Assignees: Board of Trustees of Leland Stanford Jr. Univ., President & Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Steffan N. Ho, Peter Belshaw
  • Patent number: 6015709
    Abstract: The present invention relates to chimeric transcriptional activators.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: January 18, 2000
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventor: Sridaran Natesan
  • Patent number: 6011018
    Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: January 4, 2000
    Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
  • Patent number: 5994313
    Abstract: We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 30, 1999
    Assignees: Board of Trustees of the Leland S. Stanford, Jr. Univ., President and Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
  • Patent number: 5981262
    Abstract: The molecular cloning of humansyk DNA, compositions containing same and uses thereof are disclosed.
    Type: Grant
    Filed: January 31, 1996
    Date of Patent: November 9, 1999
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Joan Brugge, Jay Morganstern, Lily Shiue, Lynne Zydowsky, Mark Zoller, Anthony Pawson
  • Patent number: 5939528
    Abstract: The invention relates to the human protein FRAP, and in particular to the FKBP12-rapamycin binding domain thereof and to the ternary complex formed by the FRB domain, rapamycin and FKBP12. A new crystalline composition comprising the ternary complex, coordinates defining its three dimensional structure in atomic detail, and uses thereof are disclosed.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: August 17, 1999
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Jon C. Clardy, Jungwon Choi
  • Patent number: 5871753
    Abstract: Methods and compositions are provided for modified cells, where a chimeric protein consisting of a ligand binding domain fused to an action domain is employed which initiates a signal which activates a biological process: transcription of at least one gene, usually a second construct introduced into the host cells; exocytosis; or an extracellular process. The second construct optimally present provides for a promoter which responds to a transcriptional activation action domain to provide for transcription, when an appropriate ligand binds to the ligand binding domain. Exemplary of the system is the use of an FKBP/CD3.zeta. or transcription factor fusion protein, using dimeric FK506 or FK520 as the ligand and a promoter responsive to NF-AT or other transcription factor requiring two molecules for transcriptional activation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 16, 1999
    Assignees: Board of Trustees of the Leland Stanford Junior University, President and Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw, Steffan Ho